Alicia Del Carmen Humanez Alvarez

Dr. Alicia Del Carmen Humanez Alvarez

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2012 in Plant Cell, Tissue and Organ Culture (PCTOC)
Verified
Journal Article
Closed access
PDF file
AAAlicia Del Carmen Humanez Alvarez
Alicia Del Carmen Humanez Alvarez
MCMiguel Angel Blasco Carlos
Miguel Angel Blasco Carlos
CBC. Brisa
C. Brisa
JSJuan Segura
Juan Segura
IAIsabel Arrillaga
Isabel Arrillaga

22 September 2011 in In Vitro Cellular & Developmental Biology - Plant
Verified
Journal Article
Closed access
PDF file
AAAlicia Del Carmen Humanez Alvarez
Alicia Del Carmen Humanez Alvarez
MCMiguel Angel Blasco Carlos
Miguel Angel Blasco Carlos
CBCarmen Brisa
Carmen Brisa
JSJuan Segura
Juan Segura
IAIsabel Arrillaga
Isabel Arrillaga

26 November 2024 in Atmosphere
Verified
Journal Article
Open access
PDF file
CPClaudia Milena Galeano Paez
Claudia Milena Galeano Paez
HGHugo Alberto Brango García
Hugo Alberto Brango García
KPKarina Susana Pastor
Karina Susana Pastor
ACAndrés Coneo-Pretelt
Andrés Coneo-Pretelt
GAGean Carlos Arteaga Arroyo
Gean Carlos Arteaga Arroyo
LELyda Espitia-Pérez
Lyda Espitia-Pérez
This study evaluates the cytotoxic and genotoxic effects of PM2.5 collected from an open-cast coal mining area in northern Colombia. Cyclohexane (CH), dichloromethane (DCM), and acetone (ACE) extracts were obtained using Soxhlet extraction to isolate compounds of different polarities. Human lymphocytes were exposed to the extracted compounds, and cytotoxicity and genotoxicity were assessed using the cytokinesis block micronucleus (CBMN) and comet assays, incorporating FPG and ENDO III enzymes to detect oxidative DNA damage. Chemical analysis revealed that the organic fractions consisted mainly of modified hydrocarbons and volatile organic compounds. The CBMN assay showed a significant increase in micronuclei in binucleated (MNBN) and mononucleated (MNMONO) cells and nucleoplasmic bridges (NPB) in exposed lymphocytes. The comet assay revealed substantial oxidative DNA damage, particularly with the ACE extract, which significantly increased oxidized purines and pyrimidines. DCM induced similar effects, while CH showed moderate effects. CREST immunostaining revealed aneugenic activity, particularly in cells exposed to ACE and DCM extracts. These results suggest that polar fractions of PM2.5, likely containing metals and modified PAHs, contribute to DNA damage and chromosomal instability. The study highlights the need to monitor the composition of PM2.5 in mining regions to implement stricter environmental policies to reduce exposure and health risks.

Verified
Journal Article
Open access
PDF file
ATAna Marcela Peñata Taborda
Ana Marcela Peñata Taborda
Pedro Juan Espitia-PérezPedro Juan Espitia-Pérez
Pedro Juan Espitia-Pérez
LELyda Espitia-Pérez
Lyda Espitia-Pérez
ACAndrés Coneo-Pretelt
Andrés Coneo-Pretelt
HGHugo Alberto Brango García
Hugo Alberto Brango García
MNMario Negrette
Mario Negrette
Considering the limitations of monotherapies due to chemoresistance and side effects, this research aimed to determine whether low doses of sulforaphane (SFN) combined with docetaxel (DCT) could enhance therapeutic efficacy. Prostate cancer cell lines LNCaP and PC-3 were treated with individual IC50 doses of SFN and DCT and half-reduced IC50 values for the SFN:DCT combination. Metabolic markers, including glucose consumption, lactate production, reactive oxygen species (ROS), mitochondrial mass, and caspase activity, were assessed. In LNCaP cells, the SFN:DCT combination reduced cell viability to 50%, comparable to DCT monotherapy (48%). Caspase 3 activation was also higher with SFN:DCT (2.4 ± 0.75 RFU) than DCT alone (2.1 ± 0.47 RFU), while caspase 8 activation remained comparable, indicating equivalent effectiveness at lower concentrations. In PC-3 cells, the combination induced caspase 3 activation (1.16 ± 0.0484 RFU) at levels slightly lower than DCT (1.51 ± 0.2062 RFU) but achieved greater reductions in mitochondrial mass, reflecting its ability to target metabolic vulnerabilities in aggressive phenotypes. Our findings suggest that the SFN:DCT combination is a promising strategy for early-stage prostate cancer. By achieving comparable efficacy to DCT monotherapy at low doses, the SFN:DCT combination maintains the therapeutic impact, mitigating the adverse effects of conventional DCT treatment.

12 June 2018
Verified
Book Chapter
Closed access
PDF file
MCMaria Cano
Maria Cano
AMAngeles Morcillo
Angeles Morcillo
AAAlicia Del Carmen Humanez Alvarez
Alicia Del Carmen Humanez Alvarez
IMIsabel Mendoza-Poudereux
Isabel Mendoza-Poudereux
AAAlex Alborch
Alex Alborch
IAIsabel Arrillaga
Isabel Arrillaga

1 July 2017 in Revista Colombiana de Biotecnología
Verified
Journal Article
Open access
EBEder Durango Ballesteros
Eder Durango Ballesteros
AAAlicia Del Carmen Humanez Alvarez
Alicia Del Carmen Humanez Alvarez